Photodynamic Therapy in Treatment of Verrucae

Verruca Vulgaris Clinical Trial

Official title:

PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04620785
• Other study ID #: 0106171
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2020
• Est. completion date: May 1, 2022

Study information

• Verified date: July 2021
• Source: Alexandria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL versus IPL only in treatment of warts.

Description:

This study will be conducted on:

Eighty patients suffering of verruca (male and female) divided randomly into three groups:

group A, B&C :

Group A: 30 patients will undergo photodynamic therapy using intralesional 4%methylene blue solution and IPL.

Group B: 30 patients will undergo IPL only. Group C (control group):20 patients will undergo intralesional saline.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: May 1, 2022
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Age:Above 16 years old.

2. Sex:Both males and female patients.

3. Clinically and dermoscopically documented verruca.

4. No verruca treatment in the last 2 weeks.

Exclusion Criteria:

1. History of photosensitivity disorder.

2. Pregnant and lactating females.

3. Diseases with risk of koebnerization e.g. Psoriasis and Lichen planus.

4. Anogenital warts.

5. Warts on head and neck.

Related Conditions & MeSH terms

• Verruca Vulgaris
• Warts

Intervention

Other:
• methylene blue / IPL
therapeutic
• IPL
therapeutic
• saline
placebo

Locations

Country	Name	City	State
Egypt	Alexandria University Faculty of Medicine	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disappearance of verruca	clinical and dermoscopic cure	10 weeks